Every NR4A2 paper, in plain English

Propofol protects H9C2 cells against hypoxia/reoxygenation injury through miR-449a and NR4A2.

Qian Q, Xie Y

This study shows that propofol protects heart cells from oxygen-deprivation damage by regulating specific molecular pathways involving NR4A2. The findings are based entirely on experiments with rat heart muscle cells in a laboratory dish.

• Propofol reduces cell death and boosts survival in heart cells exposed to low oxygen.
• The protective effect relies on increasing NR4A2 levels by suppressing miR-449a.
• Blocking NR4A2 eliminates the benefits of propofol treatment.
• Research uses only rat heart cell lines, not human subjects or animal models.

Identification of the Crucial Gene in Overflow Arteriovenous Fistula by Bioinformatics Analysis.

Zhao Z, Fu Q, Hu L, Liu Y

This bioinformatics study identifies NR4A2 as one of ten hub genes associated with intimal hyperplasia in arteriovenous fistulas, a condition involving abnormal blood vessel thickening. The research focuses on vascular remodeling and inflammation pathways rather than neurological development or function.

• NR4A2 appears as a hub gene in bioinformatics analysis of AV fistula tissue.
• The study links NR4A2 to MAPK signaling in vascular contexts, not the brain.
• No human clinical data or patient phenotypes are presented.
• Findings relate to blood vessel stenosis, unrelated to NR4A2 syndrome symptoms.

Bisphenol A exposure induces neurobehavioral deficits and neurodegeneration through induction of oxidative stress and activated caspase-3 expression in zebrafish brain.

Sahoo PK, Aparna S, Naik PK, Singh SB, Das SK

Chronic exposure to Bisphenol A causes neurodegeneration and motor dysfunction in zebrafish by triggering oxidative stress and cell death. The study observes a significant decrease in Nurr1, the protein encoded by NR4A2, alongside other dopaminergic markers.

• BPA exposure reduces Nurr1 levels in zebrafish brains.
• The chemical induces motor deficits and Parkinson-like symptoms.
• Neurodegeneration involves oxidative stress and increased cell death.
• This is a preclinical animal model study, not human research.

Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance.

Borg ML, Massart J, De Castro Barbosa T, Archilla-Ortega A, Smith JAB, Lanner JT, Alsina-Fernandez J, Yaden B, Culver AE, Karlsson HKR, Brozinick JT, Zierath JR

This study shows that a modified peptide improves muscle mass and function in mice with obesity or immobilization. The treatment increases the expression of Nr4a2, among other genes, suggesting it modulates muscle protein synthesis and degradation pathways.

• Modified UCN2 peptide increases skeletal muscle mass in obese and immobilized mice.
• Treatment upregulates Nr4a2 expression in mouse skeletal muscle tissue.
• The therapy prevents force loss from disuse and reduces muscle wasting.
• Effects involve modulation of anabolic and catabolic signaling pathways.

Developmental Inhibition of Long Intergenic Non-Coding RNA, HOTAIRM1, Impairs Dopamine Neuron Differentiation and Maturation.

Cui X, Pertile RAN, Du Z, Wei W, Sun Z, Eyles DW, Kesby JP

Inhibiting the long non-coding RNA HOTAIRM1 disrupts the development and maturation of dopamine neurons in both human cell lines and mouse models. This study identifies HOTAIRM1 as a critical regulator of early dopamine neuron specification, distinct from the NR4A2 transcription factor pathway.

• HOTAIRM1 inhibition reduces key dopamine neuron specification factors.
• The study uses human neuroblastoma cells and mouse embryos.
• Results link HOTAIRM1 to broader neurodevelopmental disorders like schizophrenia.
• No direct connection to NR4A2 variants or human clinical data is shown.

Construction of Competing Endogenous RNA Networks Incorporating Transcription Factors to Reveal Differences in Granulosa Cells from Patients with Endometriosis.

Wu R, Li J, Li J, Zhang N, Zhou W, Ren L, Chen Q, Li Y

This study identifies NR4A2 as a key gene within a regulatory network in granulosa cells from patients with endometriosis. The findings describe molecular differences in ovarian tissue related to infertility, not neurological development or function.

• NR4A2 appears in a ceRNA network in human granulosa cells from endometriosis patients.
• The study focuses on infertility mechanisms, not NR4A2-related neurodevelopmental syndromes.
• No clinical data, treatments, or neurological phenotypes for NR4A2 children are presented.

Retraction.

This paper was retracted because its data images were duplicated from other studies, making the results unreliable and the conclusions invalid.

• The study's data were found to be duplicated
• Results cannot be trusted due to image manipulation
• Conclusions are no longer valid
• The paper was officially retracted

Transcriptional Profiling of Monocytes Deficient in Nuclear Orphan Receptors NR4A2 and NR4A3 Reveals Distinct Signalling Roles Related to Antigen Presentation and Viral Response.

Phelan DE, Shigemura M, Aldhafiri S, Mota C, Hall TJ, Sznajder JI, Murphy EP, Crean D, Cummins EP

This study examines how NR4A2 and NR4A3 proteins influence immune cell function in monocytes, specifically regarding antigen presentation and viral responses. It provides mechanistic insights into these receptors' roles outside the nervous system but does not address their impact on neurodevelopment or motor symptoms relevant to your child.

• NR4A2 regulates antigen processing and MHC gene expression in monocytes.
• NR4A3 primarily influences pathways related to viral responses.
• Both receptors play common roles in regulating cell migration.
• The study uses RNA-sequencing on immune cells, not neural tissue.
• Findings focus on immunology rather than neurological development or function.

Efficient generation of dopaminergic induced neuronal cells with midbrain characteristics.

Ng YH, Chanda S, Janas JA, Yang N, Kokubu Y, Südhof TC, Wernig M

Researchers demonstrate that combining specific transcription factors efficiently converts stem cells into functional midbrain-like dopaminergic neurons. This method improves the reproducibility and authenticity of these cells compared to traditional differentiation techniques. The study provides a robust protocol for generating these specific neuron types in both mouse and human models.

• Combining Ascl1, Lmx1a, Nurr1, En1, FoxA2, and Pitx3 generates functional midbrain dopaminergic neurons.
• Transcription factor programming yields synchronous and efficient differentiation from pluripotent stem cells.
• The approach works for both mouse and human induced neuronal cells.
• Complex factor combinations are necessary for proper regional specification of induced neurons.

Analogs of the Dopamine Metabolite 5,6-Dihydroxyindole Bind Directly to and Activate the Nuclear Receptor Nurr1.

Kholodar SA, Lang G, Cortopassi WA, Iizuka Y, Brah HS, Jacobson MP, England PM

Researchers identified a stable chemical analog that directly activates Nurr1, the protein affected by NR4A2 mutations. This compound stimulates the production of dopamine-related genes in laboratory settings.

• The study uses cell-based assays to test chemical binding to Nurr1.
• No human patients or animal models are included in this research.
• Findings do not demonstrate clinical efficacy or safety for treatment.

Matrigel enhances differentiation of human adipose tissue-derived stem cells into dopaminergic neuron.

Absalan F, Pasandi MS, Ghasemi Hamidabadi H, Saeednia S, Bojnordi MN, Zahiri M, Alizadeh R, Bagher Z

This study shows that human stem cells from fat tissue can turn into dopamine-producing neurons when grown in a specific gel, suggesting potential for Parkinson's disease modeling. It does not test treatments on people with NR4A2-related syndromes or address the genetic mechanisms relevant to this child.

• Human adipose stem cells differentiate into dopaminergic neurons in 3D Matrigel culture.
• Cells grown in Matrigel show higher survival and dopamine release than standard cultures.
• The study focuses on Parkinson's disease models, not NR4A2-related neurodevelopmental disorders.
• No clinical trials or human patient data for NR4A2 variants are included.

Inhibition of miR-145-5p Reduces Spinal Cord Injury-Induced Inflammatory and Oxidative Stress Responses via Affecting Nurr1-TNF-α Signaling Axis.

Jiang L, Wei ZC, Xu LL, Yu SY, Li C

Inhibiting miR-145-5p reduces inflammation and oxidative stress in spinal cord injury models by restoring Nurr1 levels and blocking TNF-α signaling. This study demonstrates a molecular mechanism where miR-145-5p directly targets Nurr1, but it does not test treatments for NR4A2-related syndromes or human patients.

• The study uses rat spinal cord injury models and cell cultures, not human participants.
• Inhibiting miR-145-5p increases Nurr1 expression and reduces inflammatory markers.
• Nurr1 acts as a direct target of miR-145-5p in this specific pathway.
• The findings relate to spinal cord injury mechanisms, not NR4A2 syndrome treatment.

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.

Mazzocchi M, Goulding SR, Wyatt SL, Collins LM, Sullivan AM, O'Keeffe GW

The HDAC4/5 inhibitor LMK235 protects dopaminergic neurons from degeneration in cell and tissue culture models of Parkinson's disease. This protection occurs through increased histone acetylation and activation of BMP-Smad signaling pathways.

• LMK235 inhibits HDAC4 and HDAC5 enzymes in laboratory cell models.
• Treatment increases neurite outgrowth in human SH-SY5Y cells and rat midbrain neurons.
• LMK235 prevents neuron death caused by the toxin MPP+.
• LMK235 protects against alpha-synuclein-induced axonal degeneration in culture.
• Effects require BMP-Smad-dependent transcription signaling.

The molecular and epigenetic mechanisms of innate lymphoid cell (ILC) memory and its relevance for asthma.

Verma M, Michalec L, Sripada A, McKay J, Sirohi K, Verma D, Sheth D, Martin R, Dyjack N, Seibold MA, Knapp JR, Tu TH, O'Connor BP, Gorska MM, Alam R

This study investigates how innate lymphoid cells develop memory responses in asthma using mouse models and cellular analysis. It identifies specific genetic and epigenetic mechanisms, including the role of Nr4a2, that drive allergic inflammation in the lungs.

• Researchers use mouse models to study immune memory in asthma.
• The paper focuses on innate lymphoid cells, not dopaminergic neurons.
• Nr4a2 appears as a gene regulator within immune cell pathways.
• Findings relate to allergic airway disease mechanisms in mice.
• No human clinical data or NR4A2 syndrome treatment is presented.

Nurr1 deficiency shortens free running period, enhances photoentrainment to phase advance, and disrupts circadian cycling of the dopamine neuron phenotype.

Partington HS, Nutter JM, Eells JB

Nurr1 deficiency disrupts the natural daily cycling of dopamine neuron numbers and alters circadian rhythms in mice. This suggests that normal Nurr1 function is required to maintain healthy fluctuations in dopamine systems throughout the day.

• Nurr1-deficient mice show shorter free-running circadian periods.
• These mice entrain faster to phase-advanced light shifts.
• Normal dopamine neuron numbers fluctuate significantly across the day.
• Nurr1 deficiency eliminates this daily cycling of dopamine neurons.
• Fewer dopamine neurons are present at specific times in deficient mice.

Controlling for activity-dependent genes and behavioral states is critical for determining brain relationships within and across species.

Biegler MT, Cantin LJ, Scarano DL, Jarvis ED

NR4A2 expression levels change based on brain activity and behavior, meaning it cannot reliably map brain structure or identify homologous regions across species. This finding clarifies that NR4A2 is an activity-dependent marker rather than a stable structural identifier in the brain.

• NR4A2 is an activity-dependent gene, not a fixed structural marker.
• Behavioral state significantly alters NR4A2 expression patterns in the brain.
• Previous homology maps using NR4A2 are likely inaccurate or incomplete.
• This study focuses on comparative anatomy, not human disease mechanisms.
• The paper does not address NR4A2 mutations or clinical phenotypes.

Quantitative Immunohistochemistry to Measure Regional Expression of Nurr1 in the Brain and the Effect of the Nurr1 Heterozygous Genotype.

Kummari E, Guo-Ross SX, Partington HS, Nutter JM, Eells JB

This study maps Nurr1 protein levels across different brain regions in mice and shows that having only one working copy of the gene reduces protein amounts by roughly a quarter to half. It also finds that brief seizures cause temporary spikes in Nurr1 levels in specific hippocampal areas before returning to normal. The research provides baseline data on how Nurr1 is distributed in the brain but does not test treatments or analyze human patients.

• Nurr1 protein levels vary significantly across different mouse brain regions.
• Heterozygous mice show a 21-49% reduction in Nurr1 protein compared to normal mice.
• Seizures cause temporary increases in Nurr1 in the dentate gyrus within hours.
• The study uses only mouse models and does not involve human participants.
• No therapeutic interventions or clinical outcomes are reported.

Implantation of human olfactory ecto-mesenchymal stem cells restores locomotion in a rat model of Parkinson's disease.

Farhadi M, Boroujeni ME, Kamrava SK, Bagher Z, Tehrani AM, Aghajanpour F, Ezi S, Soltani R, Khatmi A, Alizadeh R

Transplanting human stem cells into the brains of rats with Parkinson's disease restores movement and increases markers associated with dopamine neuron function. This preclinical study demonstrates that these specific stem cells can improve motor symptoms in an animal model, but it does not provide evidence for treatment in humans or children with NR4A2-related syndromes.

• Human stem cells improved movement in rats with Parkinson's disease.
• The treatment increased dopamine-related markers in the brain tissue.
• This is an animal study, not a human clinical trial.
• No data exists for NR4A2 mutations or pediatric patients.

DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.

Takeda Y, Demura M, Yoneda T, Takeda Y

This study examines how DNA methylation regulates blood pressure genes in cardiovascular disease, noting that methylation can block the binding of NR4A2 (NURR1) to DNA. The research focuses on heart and adrenal gland physiology rather than neurological development or motor symptoms associated with NR4A2 syndromes.

• NR4A2 binding to DNA diminishes when its recognition sites are methylated.
• The paper links gene methylation to cardiovascular diseases like hypertension.
• Findings focus on heart and adrenal tissue, not the brain or nervous system.
• No clinical data or treatment implications for NR4A2-related neurodevelopmental disorders.

Dibutyl phthalate disrupts conserved circadian rhythm in Drosophila and human cells.

Liu W, Cao H, Liao S, Kudłak B, Williams MJ, Schiöth HB

Exposure to dibutyl phthalate (DBP), a common plasticizer, disrupts circadian rhythm regulation in both fruit flies and human cells. The study identifies that DBP alters the expression of NR4A2 (Hr38 in flies) and other core clock genes, leading to behavioral changes in flies and cellular proliferation issues in human breast cells.

• DBP exposure disrupts circadian rhythm gene expression in Drosophila and human cells.
• NR4A2 (Hr38) expression is altered by DBP, affecting downstream signaling pathways.
• DBP modifies adult fruit fly circadian behavior without impacting eye development.
• DBP promotes proliferation and migration in human breast cells at disruptive doses.

Magnetic Targeting of Human Olfactory Mucosa Stem Cells Following Intranasal Administration: a Novel Approach to Parkinson's Disease Treatment.

Simorgh S, Bagher Z, Farhadi M, Kamrava SK, Boroujeni ME, Namjoo Z, Hour FQ, Moradi S, Alizadeh R

This study demonstrates that magnetically targeting stem cells delivered through the nose improves motor symptoms and increases dopaminergic markers in rats with Parkinson's disease. The approach enhances the therapeutic effect of olfactory stem cells by directing them to the injured brain area.

• Magnetic targeting directs stem cells to the brain via the nose in rat models.
• Treatment reduces motor dysfunction and boosts dopaminergic neuron markers.
• The study uses animal models, not human patients or NR4A2 genetics.

Correction to Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.

Munoz-Tello P, Lin H, Khan P, de Vera IMS, Kamenecka TM, Kojetin DJ

This paper corrects previous findings regarding which NR4A ligands directly bind and modulate the Nurr1 receptor. It clarifies the molecular interactions of these compounds without introducing new clinical data or treatments.

• The study corrects prior errors in identifying NR4A ligands that bind Nurr1.
• It refines understanding of how specific molecules modulate the orphan nuclear receptor.
• The work focuses on molecular binding mechanics rather than therapeutic outcomes.
• No human trials or clinical applications are reported in this correction.

Caveolin-1 downregulation promotes the dopaminergic neuron-like differentiation of human adipose-derived mesenchymal stem cells.

Han C, Wang YJ, Wang YC, Guan X, Wang L, Shen LM, Zou W, Liu J

This study shows that reducing caveolin-1 levels helps human fat-derived stem cells turn into dopamine-producing neurons in a lab dish. The researchers used RNA interference to lower caveolin-1, which increased the expression of key dopaminergic markers like Nurr1 and tyrosine hydroxylase. This suggests caveolin-1 acts as a brake on this specific cell differentiation process.

• Caveolin-1 levels drop when stem cells become dopamine neurons.
• Silencing caveolin-1 boosts dopaminergic marker expression in fat stem cells.
• The study uses human adipose-derived mesenchymal stem cells.
• Findings are limited to in vitro cell culture models.
• No animal or human clinical data is presented.

NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease.

Gao H, Wang D, Jiang S, Mao J, Yang X

Blocking the inflammatory protein NF-κB in damaged nerve cells restores levels of Nurr1 and dopamine-producing markers, thereby reducing inflammation. This suggests that inhibiting NF-κB could protect dopaminergic neurons from inflammatory damage.

• Inhibiting NF-κB increases cell survival in inflamed nerve cells.
• NF-κB inhibition restores Nurr1 and dopamine marker levels.
• The study uses PC12 rat cells, not human patients.
• No clinical treatment or trial data is presented.

DNA methylation and exposure to violence among African American young adult males.

Saadatmand F, Gurdziel K, Jackson L, Kwabi-Addo B, Ruden DM

Exposure to violence alters DNA methylation patterns in genes related to the central nervous system and immune function. The study identifies specific epigenetic changes in NR4A2 and other stress-response genes associated with high levels of violence exposure.

• Violence exposure correlates with altered DNA methylation in CNS and immune-related genes.
• NR4A2 shows higher methylation levels in individuals with low violence exposure.
• Other identified genes include NR4A3, HDAC4, SHANK2, and NRG1.
• Findings suggest violence impacts epigenetic regulation of stress response pathways.

A single-cell survey of the human glomerulonephritis.

Chen Z, Zhang T, Mao K, Shao X, Xu Y, Zhu M, Zhou H, Wang Q, Li Z, Xie Y, Yuan X, Ying L, Zhang M, Hu J, Mou S

This study maps the cellular changes in various kidney diseases using single-cell sequencing and identifies NR4A2 as a gene highly expressed in membranous nephropathy. The research focuses entirely on kidney pathology and immune responses, with no connection to NR4A2-related neurological syndromes or dopaminergic function.

• NR4A2 appears as a marker for membranous nephropathy, not neurological disease.
• The study analyzes kidney tissue from patients with glomerulonephritis and related conditions.
• No findings relate to NR4A2 syndrome, Parkinson's, or dopaminergic neurons.
• This is basic molecular biology of kidney disease with no clinical relevance to the child.

microRNAs (miR 9, 124, 155 and 224) transdifferentiate mouse macrophages to neurons.

Challagundla N, Agrawal-Rajput R

This study demonstrates that specific microRNAs can reprogram mouse macrophages into functional neurons in a laboratory setting. The research provides proof-of-concept for direct cellular reprogramming but does not involve human patients or NR4A2-specific genetic mechanisms.

• Mouse macrophages convert to functional neurons using four specific microRNAs.
• The process avoids exogenous transcription factors and teratoma formation risks.
• Reprogrammed neurons show electrical activity and calcium responses.
• Bone marrow and blood cells also undergo this transdifferentiation.
• No human data or NR4A2 gene targeting is included.

Exosomal miR-409-3p secreted from activated mast cells promotes microglial migration, activation and neuroinflammation by targeting Nr4a2 to activate the NF-κB pathway.

Hu L, Si L, Dai X, Dong H, Ma Z, Sun Z, Li N, Sha H, Chen Y, Qian Y, Zhang Z

This study shows that activated mast cells release exosomes containing miR-409-3p, which enter microglial cells and trigger neuroinflammation by suppressing the NR4A2 protein. This mechanism highlights a specific molecular pathway where NR4A2 normally acts to restrain inflammatory responses in the brain.

• Mast cell exosomes deliver miR-409-3p to microglia, promoting their activation and migration.
• miR-409-3p targets and suppresses NR4A2, leading to increased NF-κB inflammatory signaling.
• NR4A2 functions as a brake on neuroinflammation in this specific mast cell-microglia interaction.
• The findings rely entirely on murine cell cultures and do not involve human patients.

Impaired neurite development and mitochondrial dysfunction associated with calcium accumulation in dopaminergic neurons differentiated from the dental pulp stem cells of a patient with metatropic dysplasia.

Sun X, Kato H, Sato H, Torio M, Han X, Zhang Y, Hirofuji Y, Kato TA, Sakai Y, Ohga S, Fukumoto S, Masuda K

A specific genetic mutation in the TRPV4 channel causes calcium buildup and mitochondrial failure in dopaminergic neurons, leading to impaired nerve growth. This study identifies mitochondrial dysfunction as a potential therapeutic target for neuropsychiatric symptoms associated with this unrelated skeletal disorder.

• TRPV4 gain-of-function mutations disrupt calcium balance in dopaminergic neurons.
• Mutant neurons show impaired neurite development and reduced energy production.
• Mitochondrial dysfunction drives the neurodevelopmental defects observed in this model.
• Targeting mitochondria may alleviate neuropsychiatric symptoms in TRPV4-related diseases.

Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.

Willems S, Ohrndorf J, Kilu W, Heering J, Merk D

Researchers identify small chemical fragments that activate the Nurr1 protein in human cells, providing new tools to study how this receptor works. These compounds enhance gene expression and promote protein interactions but remain early-stage research tools rather than treatments.

• Small chloroquinolineamine fragments activate Nurr1 transcriptional activity in human astrocytes.
• Compounds induce Nurr1 dimerization and recruit co-regulators to the ligand binding domain.
• Findings clarify Nurr1 activation mechanisms but do not test efficacy in animals or humans.
• These molecules serve as chemical biology tools for future drug discovery efforts.

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.

Kambey PA, Kanwore K, Ayanlaja AA, Nadeem I, Du Y, Buberwa W, Liu W, Gao D

This review hypothesizes that low levels of the NR4A2 protein cause GDNF therapy to fail in Parkinson's disease by preventing the production of new dopamine neurons. It suggests that restoring NR4A2 function could be a necessary step for such treatments to work.

• GDNF trials failed in humans despite success in animal models.
• NR4A2 is required for GDNF to stimulate dopamine neuron growth.
• Low NR4A2 levels may explain why GDNF therapy does not help patients.

The Pathology of Morphine-Inhibited Nerve Repair and Morphine-Induced Nerve Damage Is Mediated via Endoplasmic Reticulum Stress.

Liu J, Yi S, Shi W, Zhang G, Wang S, Qi Q, Cong B, Li Y

Acute and prolonged morphine exposure damages nerve cells in the rat brain's cortex, impairs the growth and development of new neurons, and activates a stress response in cellular structures called the endoplasmic reticulum. This stress response is linked to the reduced activity of NURR1, a protein important for brain cell health and function.

• Morphine harms brain nerve cells in rats
• New neuron growth is blocked by morphine
• Endoplasmic reticulum stress is triggered by morphine
• NURR1 levels drop with morphine use
• This stress may stop brain repair after injury

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington's Disease Mice.

Hecklau K, Mueller S, Koch SP, Mehkary MH, Kilic B, Harms C, Boehm-Sturm P, Yildirim F

Inhibiting specific enzymes in the brains of Huntington's disease mice partially corrects gene expression errors, including those involving NR4A2, and modestly improves motor coordination. This preclinical study does not test treatments for NR4A2-related syndrome or demonstrate clinical benefits in humans.

• HDAC1/3 inhibition normalizes NR4A2 gene expression in Huntington's disease mouse models.
• Treatment yields only modest improvements in motor skill learning and coordination deficits.
• The therapy does not reverse brain atrophy or affect anxiety-like behaviors in mice.
• This is a preclinical study with no human clinical data or direct relevance to NR4A2 syndrome treatment.

Novel peripheral role of Nurr-1/GDNF/AKT trajectory in carvedilol and/or morin hydrate hepatoprotective effect in a model of hepatic ischemia/reperfusion.

El Sayed NF, Abdallah DM, Awad AS, Ahmed KA, El-Abhar HS

Carvedilol and morin hydrate protect the liver from injury in a rat model by activating the Nurr-1/GDNF/AKT pathway, reducing inflammation and cell death, boosting antioxidant defenses, and enhancing cellular cleanup processes. The combination of both drugs works better than either alone.

• Nurr-1/GDNF/AKT pathway is key to liver protection
• Drugs reduce inflammation and cell death
• Combination therapy is more effective
• Enhances cellular cleanup and antioxidant defenses
• Improves liver function and structure

PT3: A Novel Benzamide Class Histone Deacetylase 3 Inhibitor Improves Learning and Memory in Novel Object Recognition Mouse Model.

Pulya S, Mahale A, Bobde Y, Routholla G, Patel T, Swati, Biswas S, Sharma V, Kulkarni OP, Ghosh B

This preclinical study shows that a new drug called PT3 improves memory and increases the expression of NR4A2 in mice. The findings are limited to animal models and do not provide evidence for human treatment or safety.

• PT3 is an HDAC3 inhibitor that crosses the blood-brain barrier in mice.
• Treatment improved long-term memory in a mouse behavioral test.
• NR4A2 expression increased in mouse brain tissue after PT3 administration.
• The study focuses on age-related memory loss and Alzheimer's disease models.
• No human clinical data or NR4A2 syndrome-specific outcomes are reported.

Targeting NR4A Nuclear Receptors to Control Stromal Cell Inflammation, Metabolism, Angiogenesis, and Tumorigenesis.

Crean D, Murphy EP

This review explains how NR4A receptors regulate inflammation, metabolism, and tumor growth in stromal cells. It focuses on the role of these receptors in rheumatoid arthritis and cancer rather than neurological development or movement disorders.

• NR4A receptors act as sensors for cellular stress and inflammation in the body.
• The paper reviews NR4A1 and NR4A2 roles in stromal cell behavior and immune response.
• It discusses how these receptors influence tissue hyperplasia and angiogenesis in arthritis.
• The text covers NR4A involvement in tumor-stromal communication and cancer development.
• No clinical data or treatment strategies for NR4A2-related neurodevelopmental conditions are presented.

Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice.

Sheng Y, Ma R, Yu C, Wu Q, Zhang S, Paulsen K, Zhang J, Ni H, Huang Y, Zheng Y, Qian Z

This study found that reduced c-Myc levels impair blood stem cell function in mice by affecting genes like NR4A2, which are important for stem cell survival and dormancy. The results suggest that c-Myc influences blood cell development through interactions with NR4A2 and other genes, and may affect how stem cells respond to signals from their environment. However, the findings are specific to blood stem cells and mouse models, not directly about NR4A2-related syndrome in humans.

• c-Myc regulates NR4A2 and other genes critical for blood stem cell function
• NR4A2 helps maintain blood stem cell dormancy and survival
• Reduced c-Myc improves outcomes in mice with defective blood cell development
• Findings are in mouse blood stem cells, not human NR4A2 syndrome
• No direct therapeutic implications for NR4A2-related neurodevelopmental disorders

Role of the Orphan Nuclear Receptor NR4A Family in T-Cell Biology.

Odagiu L, May J, Boulet S, Baldwin TA, Labrecque N

This review explains how NR4A family proteins regulate T-cell development and immune responses. It does not provide information relevant to the neurodevelopmental or motor symptoms associated with NR4A2 syndrome.

• NR4A1, NR4A2, and NR4A3 act as transcription factors in T cells.
• These genes are induced during T-cell receptor triggering and antigen recognition.
• The paper reviews T-cell life cycles from thymic differentiation to peripheral responses.
• It covers immune responses against infections and cancer.
• No clinical data or neurodevelopmental insights for NR4A2 syndrome are included.

Attenuated macrophage activation mediated by microRNA-183 knockdown through targeting NR4A2.

Gong FH, Long L, Yang YS, Shen DH, Zhang YS, Wang XS, Zhang XP, Xiao XQ

This study shows that reducing a specific microRNA (miR-183) lowers inflammation in immune cells by increasing NR4A2 levels, suggesting a potential treatment for atherosclerosis. The research focuses on heart and blood vessel health rather than the neurological or developmental aspects of NR4A2-related syndromes.

• Reducing miR-183 increases NR4A2 expression in immune cells called macrophages.
• This change reduces inflammation and improves cholesterol handling in these cells.
• The findings suggest a potential therapy for atherosclerosis, not neurological conditions.
• NR4A2 acts as a downstream target of miR-183 in this inflammatory pathway.

Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.

Jang Y, Kim W, Leblanc P, Kim CH, Kim KS

This review identifies specific endogenous and synthetic molecules that bind to and activate the Nurr1 protein, which is encoded by the NR4A2 gene. It outlines how these ligands stabilize the protein's structure and suggests they may offer therapeutic potential for neurodegenerative or inflammatory conditions.

• Nurr1 has a dynamic binding pocket that allows small molecules to activate it.
• Prostaglandins and other endogenous compounds act as natural Nurr1 ligands.
• Synthetic agonists are developed to potentially treat neurodegenerative diseases.
• The paper reviews mechanisms without testing treatments in humans or NR4A2 patients.